Literature DB >> 210383

Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects.

J P Bilezikian, R E Canfield, T P Jacobs, J S Polay, A P D'Adamo, J A Eisman, H F DeLuca.   

Abstract

We determined the response of 1alpha,25-dihydroxyvitamin D3 after mithramycin-induced hypocalcemia in eight subjects with polyostotic Paget's disease of bone. Thirty-six hours after infusion of mithramycin (25 microgram per kilogram), the average calcium declined from 9.9 +/- 0.14 (S.E.M.) to 8.0 +/- 0.19 mg per deciliter (P less than 0.005). Serum parathyroid hormone increased from 122 +/- 6 to 226 +/- 36 microliter eq per milliliter (P less than 0.05), serum phosphate decreased from 3.8 +/- 0.11 to 2.9 +/- 0.14 mg per deciliter (P less than 0.005), and urinary cyclic 3,5'-adenosine monophosphate increased from 4.6 +/- 0.35 to 7.5 +/- 0.80 mumol per gram of creatinine (P less than 0.005). Serum 1alpha25-dihydroxyvitamin D3 rose from 98 +/- 12 to 332 +/- 61 pM (P less than 0.05), the increase following the changes in parathyroid hormone and phosphate by 12 to 24 hours. When this lag period was taken into account, there was a significant relation (P less than 0.01) between the increase in 1alpha,25-dihydroxyvitamin D3 and changes in parathyroid hormone (correlation coefficient, r = +0.91) and phosphate (r = -0.96). The relatively rapid response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia occurs with a time course consistent with regulation by parathyroid hormone and phosphate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210383     DOI: 10.1056/NEJM197808312990902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  11 in total

1.  The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D.

Authors:  J R Buchanan; R Santen; S Cauffman; A Cavaliere; R B Greer; L M Demers
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

Review 2.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

Review 3.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

4.  Control of plasma 1,25-(OH)2-vitamin D concentrations by calcium and phosphorus in the rat: effects of hypophysectomy.

Authors:  R W Gray
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

5.  Paget's disease of bone.

Authors:  E S Siris; T P Jacobs; R E Canfield
Journal:  Bull N Y Acad Med       Date:  1980-04

6.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.

Authors:  D M Slovik; R M Neer; J T Potts
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

8.  Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.

Authors:  S Adami; W B Frijlink; O L Bijvoet; J L O'Riordan; T L Clemens; S E Papapoulos
Journal:  Calcif Tissue Int       Date:  1982-07       Impact factor: 4.333

9.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

Authors:  J Reeve; P J Meunier; J A Parsons; M Bernat; O L Bijvoet; P Courpron; C Edouard; L Klenerman; R M Neer; J C Renier; D Slovik; F J Vismans; J T Potts
Journal:  Br Med J       Date:  1980-06-07

Review 10.  The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.

Authors:  Ladan Zand; Rajiv Kumar
Journal:  Endocrinol Metab Clin North Am       Date:  2017-09-29       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.